Friday, January 6, 2012

SandRidge Energy (SD) - Depressed Implied Vol, Elevated Realized Vol

SD is trading $8.73, unched with IV30™ down 3.6%. The LIVEVOL® Pro Summary is below.



-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------

SandRidge Energy, Inc. (SandRidge) is an independent oil and natural gas company. It is engaged in development and production activities related to the exploitation of its holdings in West Texas and the Mid-Continent area of Oklahoma and Kansas.

Earlier I wrote on SPRD and the exploding vol with accompanying growing short interest. For the second note today let's go the other direction -- depressed vol.

I found SD stock using a real-time custom scan. This one hunts for low vols.

Custom Scan Details
Stock Price GTE $7
IV30™ - HV20™ LTE -8 GTE -40
HV180™ - IV30™ GTE 7
Average Option Volume GTE 1,200
Industry != Bio-tech
Days After Earnings GTE 32

The snapshot of the scan is included (below) in case you want to build it yourself in Livevol® Pro.



The goal with this scan is to identify short-term implied vol (IV30™) that is depressed both to the recent stock movement (HV20) and the long term trend in stock movement (HV180). I'm also looking for a reasonable amount of liquidity in the options (thus the minimum average option volume), want to avoid bio-techs (and their crazy vol) and make sure I'm not purchasing depressed IV30™ relative to HV20 simply because of a large earnings move.

The SD Charts Tab is included (below). The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).



The stock portion is pretty wild. Two earnings cycles ago, the stock collapsed from $11.17 down to $6.55 two days after the report. On 12-22-2011, the stock popped from $6.67 to $8.21 on news of a PP&E sale. Here's that news snippet from The Motely Fool:

---
The company sold 363,636 net acres in the Mississippian basin to a joint venture funded by Repsol for $250 million and an additional $750 million drilling carry obligation. The venture is buying a 25% non-operated working interest in the Extension Mississippian play and a 16% non-operated working interest in the Original Mississippian play.

Sandridge Energy Shares Popped: What You Need to Know, written by Travis Hoium
---

Well, there you go. The article goes on to offer the possibility that this cash infusion could be a catalyst for future growth (and solvency).

Looking to the vol portion, we can see the stock pop pushed the historical realized vol up, but the implied has sort of, sat there. While the HV20 is "artificially" elevated because of the recent move, it is interesting to note that the implied is depressed relative to the long-term historical realized measure as well. The vol comps are:

IV30™: 62.09%
HV20: 98.67%
HV180: 80.06%

The 52 wk range in IV30™ for SD is [42.43%, 127.84%]. This puts the current implied at the 23rd percentile. In English, the implied is depressed to its own history (annual) and to the short-term and long-term realized historical vols.

Let's turn to the Skew Tab.



We can see that the Jan ATM vol is in fact the lowest vol of all strikes across all three front expiries. All three expiries demonstrate an upside skew to the OTM calls as well. The option market reflects two-sided tail risk.

The next earnings cycle for SD is likely going to be in late Feb (after Feb expo). That can explain why the Mar ATM vol is the highest of the three front months.

Finally, let's look to the Options Tab (below).



What is interesting is not just that the front three months show monotonic vol increases (earnings explains that), but that the Jun, Jan'13 an Jan'14 leaps also continue that trend. The Jan, Feb, Mar, Jun, Jan'13, Jan'14 vols are priced to 57.73%, 63.28%, 66.84%, 69.73%, 71.44% and 73.28%, respectively. Given the recent move in the stock on what was apparently a "surprise" announcement, that's... weird...

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Spreadtrum Communications (SPRD) - Short Interest Up 75%, Elevated Vol up 50%, Stock Down 40%

SPRD is trading $16.94, down 12.0% with IV30™ up 17.7%. The LIVEVOL® Pro Summary is included below.



-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------

Spreadtrum Communications, Inc. is a fabless semiconductor company that designs, develops and markets baseband processor, radio frequency (RF) transceiver and turnkey solutions for the wireless communications and mobile television market.

I found this stock using the real-time custom scan that searches for high vols relative to the short-term and long-term historical realized vol. Keep in mind, this is a company based in China so all financial reporting is essentially vetted by the command center -- i.e. the government. The risks inherent in this company (and all Chinese stocks) are quite substantial from a systematic point of view. Obviously, the firm-specific risk also always exists.

Custom Scan Details
Stock Price GTE $7 and LTE $70
IV30™ - HV20 LTE 10
HV180 - IV30™ LTE -8
Average Option Volume GTE 1,200
Industry isNot Bio-tech
Days After Earnings GTE 10 and LTE 60

The goal with this scan is to identify short-term implied vol (IV30™) that is elevated both to the recent stock movement (HV20) and the long term trend in stock movement (HV180). I'm also looking for a reasonable amount of liquidity in the options (thus the minimum average option volume), want to avoid bio-techs (and their crazy vol) and make sure I'm not selling elevated IV30™ simply because earnings are approaching.

The SPRD Charts Tab is included (below). The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).



The stock closed just under $30 on 11-16-2011 and is now down more than 43% in less than two calendar months. On the vol side, the IV30™ was as low as 67.34% on 12-23-2011. Today it's up 48% from that level in just 14 calendar days. The 52 wk range in IV30™ is [37.78%, 224.67%]. The current IV30™ is actually below the 50th percentile (annual), though it is elevated substantially to the two historical measures I like to focus on. Specifically:

IV30™: 99.54%
HV20: 67.55%
HV180: 73.24%

I did read some interesting news yesterday from The Motley fool regarding short interest in SPRD. According to an article written by Rich Duprey, with wsj.com as the source, SPRD had a 73.1% increase in shares shorted raising the total to float to nearly 10%. You can read the article here: Do the Shorts Know Something You Don't?

Let's turn to the Skew Tab, below.



I've only included the front two months. We can see a similar shape across both with a relatively "normal" skew. Neither month shows an "expected event" nor a single strike that's bid or offered substantially to the rest (wrt vol).

Finally, let's look to the Options Tab (below).



We can see Jan, Feb and May vol is priced to 100.67%, 99.23% and 95.95%, respectively. It's interesting to note that the Feb 8 puts are bid for size -- whoa...

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Pre-Market/Post Market: 1-6-12

To get an e-mail alert when a new pre-market report is posted please send an e-mail to support (support (at) livevol.com) with "Pre-market" in the subject line.

-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------



Download as .pdf: PDF Download




Download as .pdf: PDF Download

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Thursday, January 5, 2012

Molycorp (MCP) - Depressed Vol in Stock Down 60% in 6 Mos.

MCP is trading $25.33, down 0.9% with IV30™ down 0.3%. The LIVEVOL® Pro Summary is below.



-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------

Molycorp, Inc. is a rare earth oxide (REO) producer in the Western hemisphere and owns a rare earth project outside of China. The Company is in development stage. The Company focuses to be an integrated producer of rare earth products, including oxides, metals, alloys and magnets.

This another vol note surrounding depressed implied to the historical realized levels. I found MCP using a real-time custom scan. This one hunts for low vols.

Custom Scan Details
Stock Price GTE $7
IV30™ - HV20™ LTE -8 GTE -40
HV180™ - IV30™ GTE 7
Average Option Volume GTE 1,200
Industry != Bio-tech
Days After Earnings GTE 32

The snapshot of the scan is included (below) in case you want to build it yourself in Livevol® Pro.



The goal with this scan is to identify short-term implied vol (IV30™) that is depressed both to the recent stock movement (HV20) and the long term trend in stock movement (HV180). I'm also looking for a reasonable amount of liquidity in the options (thus the minimum average option volume), want to avoid bio-techs (and their crazy vol) and make sure I'm not purchasing depressed IV30™ relative to HV20 simply because of a large earnings move.

The MCP Charts Tab is included (below). The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).



MCP has fallen rather abruptly from over $60 in August to now in the mid 20's. The short-term historical realized vol has been as high as 125% (in Oct). The implied has been as high as 116.18%. Today however, the implied is s depressed to the historical measures (both long- and short-term). Specifically:

IV30™: 63.24%
HV20: 74.15%
HV180: 82.19%

The 52 wk range in IV30™ is [50.82%, %116.18]. The current level puts it in the 18th percentile (annual).

Let's next turn to the Skew Tab.



MCP has weeklies listed but I have omitted them from this chart to focus on the monthlies and keep it a little cleaner. We can see a monotonic increase from the front to the back months (the opposite of what we've seen in some other names). The next earnings release for MCP should be in the Mar cycle. It's that event that has Mar elevated to the front months. Looking back to the stock chart (above), we can see that for the last two earnings cycles MCP has gapped.

Specifically:
8-11-2011 : Stock went from $54.14 to $58.90.
11-10-2011: Stock went from $38.70 to $33.45.

Finally, let's look to the Options Tab (below).



We can see the monthly vols are 59%, 64.5% and 69.53% for Jan, Feb and Mar monthly expiries, respectively. That Mar ATM straddle ($25 strike) is priced at ~$6.20 mid-market.

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Dendreon (DNDN) - Pre-announcement Sends Bio-tech Soaring; Vol Pops, Upside Skew is Bid

DNDN is trading $10.77, up 41.7% with IV30™ up 39.1% as of ~10:30am EST. The LIVEVOL® Pro Summary is included below.



-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.

So this one has a tremendously involved history – a history I won’t recount in completeness, but only on the surface to motivate the article. Here it is, in super short, super ugly form with a two-year chart included below to help motivate the discussion. The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).



Starting simple – this is a bio-tech with its major product a prostate cancer drug called PROVENGE®. Obviously the company had massive ups and downs during the FDA review process and ultimate FDA approval. The potential market is enormous for this drug, as, for those of you that don’t know, essentially every male that survives long enough will almost certainly develop prostate cancer. Yeah, all of us…A market that large pushed the stock to over $50, with some claims so extraordinary about the market size in the future that it was… well, it was unbelievable.

The fight wasn’t over after FDA approval though because the drug is extraordinarily expensive – upwards of $100,000 / year. That’s a lot – and well out of reach for the majority of Americans (not to speak of other nationals). Another big news day came when the company won Medicare payment acceptance – in English, it’s on health insurers to pay for this thing which means the market (or potential market) opened up significantly.

Then… not so good news on sales figures – the lofty forecasts were missed, at times dramatically. Doctor acceptance was poor or slow, the stock was in the single digits after being over $50. Then, today happened.

As promised by the CEO, while the initial sales figures were poor, ultimately the drug works, and there really aren’t alternatives. So, it may have been slow to adopt, but, it’s happenin’ now. Here are some details from an article written by Adam Feuerstein of TheStreet.com.

---
Provenge gross sales for the December quarter totaled $82 million or 25% growth over third quarter sales, Dendreon said. On a net basis, analysts were expecting Provenge sales of about $70 million in the fourth quarter. Despite the apples-to-oranges comparisons, Provenge sales appear to have outperformed expectations.

[…]

"We had a strong fourth quarter that exceeded our expectations," said Dendreon CEO Mitch Gold in a statement. "As we look to 2012, we expect modest quarter-over-quarter growth while we focus on bringing additional clinics on board and converting them into steady prescribers."

Deustsche Bank analyst Robyn Karnauskas spoke to Dendreon management this morning. "They want to caution investors to continue to expect MODEST growth early next year, while still expecting 2Q/3Q uptick," she writes in an email note.
---

Well, there you go. At the very lest, while it’s good news, you can see why the company didn’t pop back to $50.

Looking back at that Chart (above), it’s interesting to note that the IV30™ has exploded to just under an annual high. This isn’t good news that deflates risk – this is good news that elevates risk further. The 52 wk range for IV30™ is [36.07%, 124.95%]. On as side note, 36% -- WTH!!!

Let’s turn to the Skew Tab below to examine the month-to-month and line-by-line vols.



We can see the monotonic vol increases from the back to the front. Further, we can see a distinct upside skew in Jan – the option market reflects substantial upside near-term potential / risk.

Earnings for DNDN are likely in the Mar cycle (when it comes out) and in the May cycle. Having said that, with bio-techs, it’s the stuff that happens in between earnings that can be the catalyst for movement (see today, for example). DNDN is unique in that it does have a product selling for tens of millions or even hundreds of millions of dollars, so earnings do matter. It’s the pre-announcements that kinda cause a frenzy.

Finally. Let’s turn to the Options Tab, for completeness.



I wrote about this one for TheStreet.com (OptionsProfits), so no specific trade analysis here. I will say that taking a holistic approach to the news over the last several years, it's reasonable to ask whether or not you think this company is going to make it. I don’t know if it’s a $50 stock (or more), but the article from TheStreet.com (quoted above) reads that the CEO wants to temper projections yet the quarter over quarter results show a 25% increase. Ummm, 25% growth in 3 months is "modest?" Ok...

This company feels like it's going to survive (if not flourish). Whether it survives as a $2 stock or a $50 stock (or higher), is just... a guess...

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Pre-Market/Post Market: 1-5-12

To get an e-mail alert when a new pre-market report is posted please send an e-mail to support (support (at) livevol.com) with "Pre-market" in the subject line.

-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------



Download as .pdf: PDF Download




Download as .pdf: PDF Download

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Wednesday, January 4, 2012

Computer Sciences (CSC) - Elevated Vol, Bad News and Allergic IV30™

CSC is trading $24.26, down 1.1% with IV30™ up 11.3%. The LIVEVOL® Pro Summary is included below.



-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------

Computer Sciences Corporation (CSC) is engaged in the information technology (IT) and professional services industry.

I found this stock using the real-time custom scan that searches for high vols relative to the short-term and long-term historical realized vol. I've included the scan details below, but this one has a little extra pattern to it which I like.

Custom Scan Details
Stock Price GTE $7 and LTE $70
IV30™ - HV20 LTE 10
HV180 - IV30™ LTE -8
Average Option Volume GTE 1,200
Industry isNot Bio-tech
Days After Earnings GTE 10 and LTE 60

The goal with this scan is to identify short-term implied vol (IV30™) that is elevated both to the recent stock movement (HV20) and the long term trend in stock movement (HV180). I'm also looking for a reasonable amount of liquidity in the options (thus the minimum average option volume), want to avoid bio-techs (and their crazy vol) and make sure I'm not selling elevated IV30™ simply because earnings are approaching.

The CSC Charts Tab is included (below). The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).



I've highlighted the elevated implied to the two historical realized vols. While the vol is popping today (more on that below), we can see that it's been much higher as recently as early Dec.

The stock has been headed down -- its annual high is $55.28 and as of this writing it's trading at $24.26. The news for CSC lately has been... well it's been the kind of news you would expect from a stock that was $55 and is now $24. I've included a couple of snippets below from the last two days.

---
Tuesday, January 3, 2012

Fitch Ratings has put its ratings on Computer Sciences Corp on Negative Watch, citing uncertainties over its health information contract with the U.K.’s National Health Service.

Last week, Standard & Poor’s cut its long-term ratings on CSC by one notch for the same reason.

CSC last week warned it may write off as much as $1.5 billion in contract investments connected to the NHS contract, and said it would revise its 2012 forecast as a result.
Source: Washington Business Journal via Yahoo! Finance: Fitch puts CSC on watch list, written by Jeff Clabaugh.
---

And today CSC was mentioned in an article entitled, J.P. Morgan: Avoid these 11 stocks, written by Meena Krishnamsetty. That's probably not a good article to be listed in... just sayin'...

The specific vol comp levels that triggered the custom scan are:

IV30™: 66.33%
HV20™: 52.93%
HV180™: 52.98%

The 52 wk range in IV30™ for CSC is [25.56%, 95.26%], so that 66.33% level, while certainly elevated, is still only in the 58th percentile (annual).  It's also worth noting that CSC IV30™ seems to have an allergic reaction to the HV180. By that I mean, every time it gets near that level (pink line), it pops above it pretty soon after.

Let's turn to the Skew Tab, below.



The skew has maintained a "normal" shape. To read what "normal" skew is and why it exists you can go here: Understanding Option Skew. Feb is elevated to Jan and Mar b/c of the next earnings release which is due out around Feb 10 (ish) based on the prior two years which saw 2-10-2010 and 2-9-2011 earnings reports. One interesting point, that Jan 20 put vol is super elevated and is in fact higher than the Feb 20 puts.

Finally, let's turn to the Options Tab, for completeness.



While I didn't include it in the skew chart, we can see that the jun option cycle is actually priced to 54 vol -- so a significant discount to the front months. CSC usually has earning sin early Feb and late May, meaning that those Jun options have two earnings cycles embedded.

DISCLOSURE: I own puts in CSC from a calendar spread where the front expired worthless.

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

MetroPCS Communications (PCS) - Elevated Near-term Tail Risk on Takeover Possibility

PCS is trading $9.01, down 4.0% with IV30™ up 3.6% as of ~10:45am EST. The LIVEVOL® Pro Summary is below.



-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------

MetroPCS Communications, Inc. (MetroPCS Communications) is a wireless telecommunications provider in the United States measured by the number of subscribers served.

PCS and Leap Wireless (LEAP) have been thrust back into the takeover mill after the AT&T / T-Mobile deal fell apart. Here’s a quick snippet from an article I’ve referenced before.

---
Leap Wireless International Inc. (LEAP) and MetroPCS Communications Inc. (PCS) may be takeover targets for bigger rivals AT&T Inc. (T) or T-Mobile USA after the larger companies’ $39 billion merger plan collapsed, JPMorgan Chase & Co. said.

The pay-as-you-go carriers could be suitable “near-term” sources of spectrum for a buyer, Phil Cusick, a JPMorgan analyst in New York, said in a note to clients today. AT&T cited a need for more spectrum as a reason for its attempt to buy T-Mobile.
Source: Bloomberg via Yahoo! Finance: Leap, MetroPCS May Be Buyout Targets for AT&T, JPMorgan Says, written by Ville Heiskanen
---

This buyout "shtuff" has created a few vol phenomena. Let’s start with the Skew Tab from Livevol® Pro.



There’s actually a lot going on here. Here’s what I see:

1. Starting simple (and rather obvious), the month-to-month vols show a monotonic increase from the back to the front, reflecting elevated risk in the near-term relative to the mid/long – term..

It’s worth noting that the next PCS earnings report should be after Feb expo. So the May options have a vol event that the Jan and Feb options do not have, yet the May vol is depressed to those front months.

2. The Jan expiry shows a parabolic skew – the upside and downside OTM options are priced to higher vol than the ATM. The option market reflects elevated tail risk in the near-term.

3. The “normal” shaped skew in May, with the OTM calls priced to lower vol than the ATM options, has created a large vol diff between the Feb and May upside skew.

Let’s next turn to the Charts Tab, below (6 months). The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).



A couple of things here that caught my eye.

1. Earnings have been a substantial event with respect to moving stock. Check out that move on 8-2-2011. PCS went from $16.18 to $10.26 in a day off of earnings and a few days later closed at $8.92. The 11-1-2011 report didn’t affect as much of a move, but still saw the stock lower by ~17% from a few days before to the day after. In English, yeah, earnings matter.

2. While the Jan vol is elevated to the back months, and Feb is elevated to May, the overall IV30™ -- which is a weighted average of the front two months – is still kinda “fair” value, as it lies in between the HV20 and HV180. Specifically:

IV30™: 72.08%
HV20: 61.73%
HV180: 75.92%

Finally, let’s turn to the Options Tab.



I wrote about this one for TheStreet.com (OptionsProfits), so no specific trade analysis here. I will say that we can see the monthly vols are priced 81%, 68% and 58% for Jan, Feb and May, respectively (top of the Options Tab). The 52 wk range in stock price for PCS is [$7.51, $18.79].

The question is whether or not PCS has a sort of "downside protection" for the near-term as the takeover possibility lingers. It's also interesting to consider whether or not the stock drops on takeover news of LEAP or if it rises on spec that it becomes an even more likely takeover candidate for the remaining field of large wireless providers. There's also that earnings vol in May -- or lack thereof. All worth examining, IMHO.

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Pre-Market/Post Market: 1-4-12

To get an e-mail alert when a new pre-market report is posted please send an e-mail to support (support (at) livevol.com) with "Pre-market" in the subject line.

-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------



Download as .pdf: PDF Download




Download as .pdf: PDF Download

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Tuesday, January 3, 2012

Cameron Int'l (CAM) - Depressed Vol into Earnings Mover

CAM is trading $50.44, up 2.5% with IV30™ up 0.9%. The LIVEVOL® Pro Summary is below.



-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------

Cameron International Corporation (Cameron) provides flow equipment products, systems and services to global oil, gas and process industries. The Company operates in three segments: Drilling & Production Systems (DPS), Process & Compression Systems (PCS) and Valves & Measurement (V&M).

I found this stock using a real-time custom scan. This one hunts for low vols.

Custom Scan Details
Stock Price GTE $7
IV30™ - HV20™ LTE -8 GTE -40
HV180™ - IV30™ GTE 7
Average Option Volume GTE 1,200
Industry != Bio-tech
Days After Earnings GTE 32

The snapshot of the scan is included (below) in case you want to build it yourself in Livevol® Pro.



The goal with this scan is to identify short-term implied vol (IV30™) that is depressed both to the recent stock movement (HV20) and the long term trend in stock movement (HV180). I'm also looking for a reasonable amount of liquidity in the options (thus the minimum average option volume), want to avoid bio-techs (and their crazy vol) and make sure I'm not purchasing depressed IV30™ relative to HV20 simply because of a large earnings move.

The CAM Charts Tab is included (below). The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).



I've highlighted a few things. In the stock portion I've highlighted the last two earnings cycles. The Summer of 2011 showed a one day move of ~$4.50. The Fall of 2011 showed a small one-day change, but five calendar days after the event, the stock was down more than $5. In English, the last two earnings cycles have seen a ~10% move in stock following the news. Why does that matter?

CAM shows depressed vol in both Jan and Feb and the next earnings release is confirmed for 2-2-2012. Tricky. The vol comps that triggered the custom scan are included below.

We can see:
IV30™: 42.67%
HV20: 54.41%
HV180: 50.23%
---
Feb: 43.56%

So Feb (with earnings) is also depressed to the two historical realized measures. Let's turn to the Skew Tab.



The skew across all three front months is "normal." More notably -- the Jan and Feb vol diff is pretty small (and earnings are outside of the Jan expiry).

Finally, let's look to the Options Tab (below).



Jan is priced to 40.81% and Feb to 43.56%. The Feb ATM straddle is priced at $~6.15 fair value (mid-market). Keeping in mind the ~$5 move surrounding the immediate time-period after the last two earnings cycles, that's... interesting...

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Barnes & Noble (BKS) - Elevated Jan Vol Reflects Upside and Downside Near-term Potential

BKS is trading $15.00, up 3.6% with IV30™ down 3.7%. The LIVEVOL® Pro Summary is below.



-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------

Barnes & Noble, Inc. (Barnes & Noble) is a bookseller. The Company is a content, commerce and technology company that provides customers access to books, magazines, newspapers and other content across its multi-channel distribution platform. As of April 30, 2011, it operated 1,341 bookstores in 50 states, 636 bookstores on college campuses, and one a Web eCommerce sites, which includes the development of digital content products and software.

This is a vol note -- both month-to-month and skew. A good start to 2012. Let's begin with the Charts Tab (6 months), below. The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20 - blue vs HV180 - pink).



On the stock side, we can see a precipitous drop from the $18 level all the way down to a close under $10 in a month (ish). Then in early/mid Nov the stock popped from the $11 range to over $18. Let's look at some of the news that drove these moves:

First, the ugliness that was mid August 2011 summarized by The Motely Fool:
---
What: Shares of Barnes & Noble (NYSE: BKS ) sank 15% in intraday trading Friday on news that Liberty Media will make a $204 million strategic investment in the beleaguered book retailer.

So what: That kind of commitment would usually be a huge positive for shareholders, but it also means that Liberty's previous $17-per-share takeover bid is now off the table. Of course, given that rumors about Liberty's change of heart were already floating around (the shares are now down 40% in August alone), today's news isn't that big of a surprise to Mr. Market.

Source: Fool.com via Yahoo! Finance: Barnes & Noble Shares Plunged: What You Need to Know, written by Brian D. Pacampara
---

And, the news that saw the stock recover in early Nov surrounded the Nook -- the BKS answer to AMZN's kindle and AAPL's iPad (sort of). CNBC highlighted the Nook as a "serious rival" to the Kindle line according an article posted on The Motely Fool, written by Anders Bylund.
Source: Barnes & Noble's Shares Surged: What You Need to Know

So there you go. A failed takeover but with investment and some hype (not meant in a derogatory way) over a new product line.

Turning to the vol portion of the chart, we can the implied has hovered around the long-term HV180 and is now essentially perfectly in line with that long-term historical realized trend.

Let's turn to the Skew Tab and we'll see a number of phenomena with the vol.



Here's what caught my eye:

1. There's a monotonic increase in vol from the back to the front across the front three expiries. The next earnings release for BKS should be near the end of Feb -- so in the Apr options, but not necessarily in Feb and certainly not in Jan. Hmmm...

2. The front two expiries show a parabolic skew reflecting both upside and downside risk, but the earnings expiry does not show that same shape.

3. Most notably to me, the Jan vol is substantially elevated to Feb and the upside skew vol diff is quite large (highlighted).

Finally, let's turn tot the Options Tab to see the specific vol numbers.



We can see the vols from Jan to Feb to Apr are 89 to 79 to 76, respectively. Further, the upside calls in Jan are priced to ~17 vol points higher than Feb. The option market reflects substantial near-term risk in BKS -- both downside instability and upside potential. This risk does not seem to surround earnings, though. That's interesting b/c for the last two earnings cycles BKS has moved 15% and -16% on 8-30-2011 and 12-1-2011, respectively. In English, earnings reports have provided significant moves in the stock price.

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html

Pre-Market/Post Market: 1-3-12

To get an e-mail alert when a new pre-market report is posted please send an e-mail to support (support (at) livevol.com) with "Pre-market" in the subject line.

-----------------------------------------------------------


Click for Free Trial

-----------------------------------------------------------



Download as .pdf: PDF Download




Download as .pdf: PDF Download

This is trade analysis, not a recommendation.

Follow Live Trades and Order Flow on Twitter: @Livevol_Pro

Legal Stuff:
http://www.livevolpro.com/help/disclaimer_legal.html